Research and Factsheets
Research
2025
Capital
Access Group - FDA extends use of XENOVIEW® to 6-year-olds
2 June 2025 (PDF - 412KB)
2025
Capital
Access Group - FY24 results - sales growth guidance
reiterated
8 May 2025 (PDF - 544KB)
2025
Capital Access Group - Investor update presentation
confirms thesis
13 March 2025 (PDF - 262KB)
2025
Capital
Access Group - FY24 update - Xenon MRI pharma research
collaboration
10 March 2025 (PDF - 262KB)
2025
Capital
Access Group - FY24 update - Even better than expected
27
February 2025 (PDF - 540KB)
Factsheets
2024
Company
Summary
December 2024 (PDF - 1.2MB)
Latest News
- Holding(s) in Company
11 September 2025 - Submission of new Phase III study protocol to FDA for expanded
indication of XENOVIEW
12 August 2025 - Block Listing Six Monthly Return
24 July 2025
About Us
Latest Annual Report
Investor Alert
Sign up for Email Alerts